Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

References

• International Diabetes AssociationThe global burden, diabetes and impaired glucose tolerance Available from: https://www.idf.org/sites/default/files/The_Global_Burden.pdfAccessed June 9, 2014
   Google Scholar
• International Diabetes AssociationThe global burden, mortalityIDF Diabetes Atlas6th ed Available from: http://www.idf.org/diabetesatlas/global-burdenAccessed June 9, 2014
   Google Scholar
• HolzGG4thKühtreiberWMHabenerJFPancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7–37)Nature199336164103623658381211
   PubMed Web of Science ®Google Scholar
• FreemanJSThe pathophysiologic role of incretinsJ Am Osteopath Assoc2007107 SupplS6S917724014
   PubMedGoogle Scholar
• NauckMABallerBMeierJJGastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetesDiabetes200453 Suppl 3S190S19615561910
   PubMed Web of Science ®Google Scholar
• AhrénBFoleyJEThe islet enhancer vildagliptin: mechanisms of improved glucose metabolismInt J Clin Pract Suppl200815981418269436
   PubMedGoogle Scholar
• BanerjeeMYounisNSoranHVildagliptin in clinical practice: a review of literatureExpert Opin Pharmacother200910162745275719874253
   PubMed Web of Science ®Google Scholar
• PalalauAITahraniAAPiyaMKBarnettAHDPP-4 inhibitors in clinical practicePostgrad Med200912167010019940419
   PubMed Web of Science ®Google Scholar
• NambaMKatsunoTKusunokiYMatsuoTMiuchiMMiyagawaJNew strategy for the treatment of type 2 diabetes mellitus with incretin-based therapyClin Exp Nephrol2013171101523135865
   PubMed Web of Science ®Google Scholar
• KonyaHTsunodaTKamitaniMAdd-on effect of sitagliptin in an obese type 2 diabetic patient with glimepiride and metformin on blood glucose control and incretin responseJ Diabetes Invest20123 Suppl 1S206
   Google Scholar
• KatsunoTIkedaHIdaKMiyagawaJNambaMAdd-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitusEndocr J201360673374223386390
   PubMed Web of Science ®Google Scholar
• KusunokiYKatsunoTMyojinMEffect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptinEndocr J201360443143923220949
   PubMed Web of Science ®Google Scholar
• ThornberryNAGallwitzBMechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)Best Pract Res Clin Endocrinol Metab200923447948619748065
   PubMed Web of Science ®Google Scholar
• Onglyza^® (saxagliptin) Full prescribing informationPrinceton, NJ, USAWilmington, DE. Bristol-Myers Sqibb/AstraZeneca Pharmaceuticals LP2009
   Google Scholar
• RosenstockJAguilar-SalinasCKleinENepalSListJChenREffect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetesCurr Med Res Opin200925102401241119650754
   PubMed Web of Science ®Google Scholar
• DeFronzoRHissaMNGarberAJOnce-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetesDiabetes200958 Suppl 1547P
   Google Scholar
• ChacraARTanGHRavichandranSListJChenRCV181-040 InvestigatorsSafety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeksDiab Vasc Dis Res20118215015921562067
   PubMed Web of Science ®Google Scholar
• HollanderPLLiJFrederichRAllenEChenRCV181-013 InvestigatorsSafety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitusDiab Vasc Dis Res20118212513521562064
   PubMed Web of Science ®Google Scholar
• PfütznerAPaz-PachecoEAllenEFrederichBChenRCV181039 InvestigatorsInitial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeksDiabetes Obes Metab201113656757621342412
   PubMed Web of Science ®Google Scholar
• FrederichRMcNeillRBerglindNFlemingDChenRThe efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trialDiabetol Metab Syndr2012413622828124
   PubMed Web of Science ®Google Scholar
• PoolsupNSuksomboonNSetwiwattanakulWEfficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysisISRN Endocrinol2012201279814622619731
   PubMedGoogle Scholar
• GrossJLKramerCKLeitãoCBEffect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysisAnn Intern Med20111541067267921576535
   PubMed Web of Science ®Google Scholar
• PhungOJSobierajDMEngelSSRajpathakSNEarly combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysisDiabetes Obes Metab201416541041724205921
   PubMed Web of Science ®Google Scholar
• KahnSEThe relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetesDiabetologia200346131912637977
   PubMed Web of Science ®Google Scholar
• MatsumotoKMiyakeSYanoMGlucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjectsDiabetes Care19972010156215689314636
   PubMed Web of Science ®Google Scholar
• PratleyREWeyerCThe role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitusDiabetologia200244892994511484070
   PubMed Web of Science ®Google Scholar
• FukushimaMSuzukiHSeinoYInsulin secretion capacity in the development from glucose tolerance to type 2 diabetesDiabetes Res Clin Pract200466 Suppl 1S37S4315563978
   PubMed Web of Science ®Google Scholar
• Fukuda-AkitaEOkitaKOkauchiYImpaired early insulin secretion in Japanese type 2 diabetes with metabolic syndromeDiabetes Res Clin Pract200879348248918006169
   PubMed Web of Science ®Google Scholar
• MandavilliACyranoskiDNews feature: Asia’s big problemNat Med200410432532715057217
   PubMedGoogle Scholar
• IwahashiHOkauchiYRyoMInsulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patientsJ Diabetes Invest201233271275
   PubMed Web of Science ®Google Scholar
• IwaoTSakaiKAndoERelative contribution of insulin secretion and sensitivity at different stages of glucose tolerance: non-obese versus obese Japanese subjectsIntern Med201453538339024583424
   PubMed Web of Science ®Google Scholar
• SeinoYFukushimaMYabeDGIP and GLP-1, the two incretin hormones: similarities and differencesJ Diabetes Invest201011–2923
   Web of Science ®Google Scholar
• ChanCNMalikVJiaWDiabetes in Asia epidemiology, risk factors, and pathophysiologyJAMA2009301202129214019470990
   PubMed Web of Science ®Google Scholar
• ParkHParkCKimYRascatiKLEfficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysisAnn Pharmacother201246111453146923136353
   PubMed Web of Science ®Google Scholar
• KimYGHahnSOhTJKwakSHParkKSChoYMDifferences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysisDiabetologia201356469670823344728
   PubMed Web of Science ®Google Scholar
• AsoYOzekiNTerasawaTSerum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylureaTransl Res20121591253122153807
   PubMed Web of Science ®Google Scholar
• HorikawaCYoshimuraYKamadaCDietary intake in Japanese patients with type 2 diabetes: analysis from Japan Diabetes Complications StudyJ Diabetes Investig201452176187
   PubMed Web of Science ®Google Scholar
• WongMCWangHHKwanMWComparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic reviewPLoS One201493e9096324614606
   PubMed Web of Science ®Google Scholar
• KawamoriRDiabetes trends in JapanDiabetes Metab Res Rev200218 Suppl 3S9S1312324979
   PubMedGoogle Scholar
• KobayashiMYamazakiKHiraoKThe status of diabetes control and antidiabetic drug therapy in Japan – a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1)Diabetes Res Clin Pract200673219820416621117
   PubMed Web of Science ®Google Scholar
• KozawaJKitamuraTNishizawaHDipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistanceJ Diabetes Invest201342190194
   PubMed Web of Science ®Google Scholar
• KadowakiTEfficacy and safety of a novel DPP-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus – the results of clinical trials in JapanJap Pharmacol Ther2013418803815
   Google Scholar
• Onglyza® (saxagliptin)A Phase II multiple dose study in Japanese patients. Summary of Product CharacteristicsTokyo, JapanKyowa Hakko Kirin Co, Ltd2009 Available from http://www.kksmile.com/druginfo/interv/ong_in.pdfAccessed June 30, 2014
   Google Scholar
• Onglyza® (saxagliptin)A Phase III long-term monotherapy trial in Japanese patients. Summary of Product CharacteristicsTokyo, JapanKyowa Hakko Kirin Co, Ltd2011 Available from http://www.kksmile.com/druginfo/interv/ong_in.pdfAccessed June 30, 2014
   Google Scholar
• Onglyza® (saxagliptin)A phase III long-term combination therapy trial in Japanese patients. Summary of Product CharacteristicsTokyo, JapanKyowa Hakko Kirin Co, Ltd2012 Available from http://www.kksmile.com/druginfo/interv/ong_in.pdfAccessed June 30, 2014
   Google Scholar
• FrederichRAlexanderJHFiedorekFTA systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesPostgrad Med20101223162720463410
   PubMed Web of Science ®Google Scholar
• MosenzonORazISciricaBMBaseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trialDiabetes Metab Res Rev201329541742623564755
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
   PubMed Web of Science ®Google Scholar
• WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327133523992602
   PubMed Web of Science ®Google Scholar
• SchernthanerGSattarNLessons from SAVOR and EXAMINE: some important answers, but many open questionsJ Diabetes Complications2262014 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• ScheenAJCardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomesPostgrad Med2013125372023748503
   PubMed Web of Science ®Google Scholar
• OuXO’LearyHABroxmeyerHEImplications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell typesBlood2013122216116923637126
   PubMed Web of Science ®Google Scholar